FDA is informing the public, especially patients, health care practitioners, and clinics, of multiple recent reports of serious adverse events experienced by patients in Nebraska who were treated with unapproved products marketed as containing exosomes.
Read more: Public Safety Alert Due to Marketing of Unapproved Stem Cell and Exosome Products